Reviews:
MicroRNA dysregulation in uveal melanoma: a new player enters the game
Metrics: PDF 2343 views | HTML 3427 views | ?
Abstract
Zheng Li1,*, Xin Yu1,*, Jianxiong Shen1, Yang Jiang2
1Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
2Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
*These authors have contributed equally to this work
Correspondence to:
Jianxiong Shen, e-mail: [email protected]
Keywords: Uveal melanoma, microRNAs, diagnosis and therapy, oncogene, tumor suppressor
Received: November 25, 2014 Accepted: December 15, 2014 Published: January 27, 2015
ABSTRACT
Uveal melanoma is the second most common form of melanoma and a predominant intraocular malignant tumor in adults. The development of uveal melanoma is a multistep process involving genetic and epigenetic alteration of proto-oncogenes and tumor-suppressor genes. Recent discoveries have shed a new light on the involvement of a class of noncoding RNA known as microRNAs (miRNAs) in uveal melanoma. A lot of miRNAs show differential expressions in uveal melanoma tissues and cell lines. Genes coding for these miRNAs have been characterized as novel oncogene and tumor-suppressor genes based on findings that these miRNAs control malignant phenotypes of uveal melanoma cells. Several studies have confirmed that dysregulation of miRNAs promotes cell-cycle progression, confers resistance to apoptosis, and enhances invasiveness and metastasis. Moreover, several miRNAs have also been shown to correlate with uveal melanoma initiation and progression, and thus may be used as biomarkers for early diagnosis and prognosis. Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of uveal melanoma and promote the development of miRNA directed-therapeutics against this disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2923